Apollon Wealth Management LLC Has $149,000 Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Apollon Wealth Management LLC cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 38.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 10,497 shares of the company’s stock after selling 6,642 shares during the quarter. Apollon Wealth Management LLC’s holdings in Takeda Pharmaceutical were worth $149,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 38.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after purchasing an additional 859 shares during the period. Headlands Technologies LLC acquired a new position in shares of Takeda Pharmaceutical in the 2nd quarter worth approximately $59,000. Hexagon Capital Partners LLC lifted its position in shares of Takeda Pharmaceutical by 34.3% in the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after purchasing an additional 1,129 shares during the period. Blue Trust Inc. lifted its position in shares of Takeda Pharmaceutical by 74.0% in the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after purchasing an additional 2,330 shares during the period. Finally, Ridgewood Investments LLC acquired a new position in shares of Takeda Pharmaceutical in the 2nd quarter worth approximately $89,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Down 0.7 %

Shares of NYSE TAK opened at $13.53 on Tuesday. The company has a market capitalization of $43.05 billion, a P/E ratio of 23.33, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The company’s 50 day moving average price is $14.22 and its 200-day moving average price is $13.84.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.